| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | GTB-5550 (B7-H3-targeted nanobody TriKE, subcutaneous) B7-H3-expressing solid tumors | Phase 1 | — | Nanomedicine | Oncology | ||
Phase 1 data readout example | GTB-5550 (B7-H3-targeted nanobody TriKE, subcutaneous) B7-H3-expressing solid tumors | Phase 1 | — | Nanomedicine | Oncology | ||
Phase 1 data readout example | GTB-5550 (B7-H3-targeted nanobody TriKE, subcutaneous) B7-H3-expressing solid tumors | Phase 1 | — | Nanomedicine | Oncology |
Recent Updates
Recently added Catalysts
GT Biopharma, Inc.$0.46
+0.02 (+4.31%)
F 18Pipeline Score Richly Valued Pharma · Clinical
Market Cap
15.87 M
EPS
-14.40
P/E Ratio
-
Value Trade
427.79 K
-2.4 %
Week
21.55 %
1 Month
-6.38 %
3 Month
-38.72 %
6 Month
-99.9 %
5 Year
-100 %
All Time
Cash Data
Cash Position
8.92 M
Monthly Burn
823.00 K
Runway
9.9 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
352.19 K
52 Week Range
0.26 - 3.85
% held by Insiders
25.07 %
% held by Institutions
6.93 %
Enterprise Value
6.85 M
Total Shares
31.55 M
Short %
7.39 %
Float Shares
29.50 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F18
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 17%
Micro Cap (rank 752 of 905)
Percentile RankGT Biopharma, Inc. has significant pipeline risk (18/100), with $71M risk-adjusted pipeline value, led by GTB-5550 in Tri-specific Killer Engager (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GTB-5550 Small molecule | Tri-specific Killer Engager | Phase 1 | NCT07541573 | 5% | $71M | RECRUITING | 175 | - | - | Jan 1, 2032 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GTB-3650 | relapsed or refractory CD33 expressing hematologic malignancies | Phase 1 | 2025-08-12 | |||
GTB-3650 | relapsed or refractory CD33 expressing hematologic malignancies | Phase 1 | 2025-08-12 | |||
GTB-3650 | relapsed or refractory CD33 expressing hematologic malignancies | Phase 1 | 2025-08-12 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GTBP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
GTBP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GTBP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GTBP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GTBP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
GTBP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GTBPA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
GT Biopharma, Inc. has commenced a Phase 1 trial for its third drug, GTB-5550, targeting solid tumors. This milestone highlights the company's unique TriKE platform, which now has three candidates in human trials. However, the company faces challenges, including a limited cash runway and the inherent risks associated with early-stage oncology trials.
Read more →GTBPThe $13 Million Company Teaching the Immune System to Hunt Cancer
GT Biopharma, a clinical-stage immuno-oncology company with a market cap of $13 million, is advancing three drug candidates in human trials. Their unique TriKE platform aims to enhance the immune system's natural killer cells to target tumors. Despite significant potential in a growing oncology market, the company faces challenges, including lack of approved products and limited cash reserves.
Read more →GTBPThree TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
GT Biopharma has initiated clinical trials for three TriKE candidates targeting various cancers. The first patient was dosed in the GTB-5550 Phase 1 trial, which utilizes a novel subcutaneous dosing method. The 2nd-generation TriKE platform is reported to be significantly more potent than its predecessor, aiming to improve treatment outcomes for patients with specific malignancies.
Read more →GTBPGT Biopharma Reports Full Year 2025 Financial Results
GT Biopharma reported its financial results for 2025, highlighting ongoing Phase 1 trials for GTB-3650 and GTB-5550. The company anticipates significant milestones in 2026, including the initiation of the GTB-5550 trial. Despite a net loss of $28.4 million, GT Biopharma maintains a strong cash position to support its operations through Q4 2026.
Read more →GTBPGT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma, Inc. will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026. Michael Breen, the Executive Chairman and CEO, will present and engage in panel discussions, along with one-on-one investor meetings. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE platform.
Read more →GTBPGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GT Biopharma has received FDA clearance for its IND application for GTB-5550, a TriKE® targeting B7-H3 in solid tumors. The Phase 1 trial is set to begin in mid-2026, focusing on advanced prostate, ovarian, and pancreatic cancers. The trial will assess safety, tolerability, and preliminary anti-tumor activity across multiple solid tumor types. This development is seen as a pivotal step in advancing immunotherapy for patients with limited treatment options.
Read more →GTBPFunctional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
GT Biopharma, Inc. has submitted an investigational new drug application for GTB-5550, a B7-H3-targeted NK cell engager aimed at treating solid tumors. This submission is part of a broader trend in precision medicine, shifting towards platform-based biologics. The company is also advancing its Phase 1 trial for GTB-3650, targeting blood cancers. Both therapies leverage GT Biopharma's proprietary TriKE platform.
Read more →GTBPGT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma has submitted an IND application for GTB-5550, a novel NK cell engager targeting B7-H3 solid tumors. The company plans to initiate a Phase 1 trial in 2026, building on insights from its ongoing GTB-3650 trial in myeloid blood cancer. The trial aims to explore safety and efficacy across multiple solid tumor types.
Read more →GTBPGT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GT Biopharma has successfully completed the safety review for Cohort 3 of its Phase 1 trial for GTB-3650, allowing progression to Cohort 4. The trial will evaluate the drug's efficacy in patients with relapsed or refractory CD33 expressing hematologic malignancies. The next update is anticipated in Q1 2026, with potential for further dose escalation.
Read more →GTBPGT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma, Inc. will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025. Michael Breen, the Executive Chairman and CEO, will represent the company at the event, which will include opportunities for one-on-one meetings. This participation highlights GT Biopharma's focus on immuno-oncology and its proprietary TriKE® platform.
Read more →GTBPGT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GT Biopharma is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company is progressing with its Phase 1 trial for GTBP-3650 and plans to submit an IND for GTB-5550 TriKE® by Q4 2025. Investors can schedule one-on-one meetings during the conference.
Read more →GTBPGT Biopharma Reports Second Quarter 2025 Financial Results
GT Biopharma reported its second quarter 2025 financial results, highlighting strong enrollment in its Phase 1 trial for GTB-3650. The trial is progressing well, with a successful safety review and early signs of immunological activity. Financially, the company has reduced R&D and SG&A expenses, but reported a net loss of $1.4 million.
Read more →GTBPGT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma has advanced to Cohort 3 of its Phase 1 trial for GTB-3650 after a successful safety review of Cohort 2. The trial evaluates GTB-3650 for relapsed or refractory CD33 expressing hematologic malignancies. Initial results from earlier cohorts show promising immune activity, with plans to release more data in 2025.
Read more →GTBPGT Biopharma Appoints New Member to its Board of Directors
GT Biopharma has appointed David C. Mun-Gavin to its Board of Directors. Mun-Gavin brings extensive executive experience from global financial institutions and will provide valuable guidance as the company approaches its first data readout for GTBP-3650. This appointment aligns with GT Biopharma's strategy to expand its NK-engager pipeline in the coming years.
Read more →GTBPGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
GT Biopharma has successfully completed Cohort 1 of its Phase 1 trial for GTB-3650, with no safety issues reported. The trial is evaluating the drug's effectiveness in treating relapsed or refractory CD33 expressing hematologic malignancies. Following positive results, the company has initiated dosing in Cohort 2 and plans to release more detailed results in 2025.
Read more →Competitive Position
How GTBP ranks across every disease it competes inCompetitive Position is a premium feature
See how GTBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial